239 related articles for article (PubMed ID: 37533862)
1. Multivalent vaccines demonstrate immunogenicity and protect against
Jan S; Fratzke AP; Felgner J; Hernandez-Davies JE; Liang L; Nakajima R; Jasinskas A; Supnet M; Jain A; Felgner PL; Davies DH; Gregory AE
Front Immunol; 2023; 14():1192821. PubMed ID: 37533862
[TBL] [Abstract][Full Text] [Related]
2. Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against
Fratzke AP; Jan S; Felgner J; Liang L; Nakajima R; Jasinskas A; Manna S; Nihesh FN; Maiti S; Albin TJ; Esser-Kahn AP; Davies DH; Samuel JE; Felgner PL; Gregory AE
Front Immunol; 2021; 12():653092. PubMed ID: 33815413
[TBL] [Abstract][Full Text] [Related]
3. Coxiella burnetii Intratracheal Aerosol Infection Model in Mice, Guinea Pigs, and Nonhuman Primates.
Gregory AE; van Schaik EJ; Russell-Lodrigue KE; Fratzke AP; Samuel JE
Infect Immun; 2019 Dec; 87(12):. PubMed ID: 31501249
[No Abstract] [Full Text] [Related]
4. Soluble antigens derived from
Gregory AE; van Schaik EJ; Fratzke AP; Russell-Lodrigue KE; Farris CM; Samuel JE
Cell Rep Med; 2021 Dec; 2(12):100461. PubMed ID: 35028605
[TBL] [Abstract][Full Text] [Related]
5.
Fratzke AP; Gregory AE; van Schaik EJ; Samuel JE
Front Immunol; 2021; 12():754712. PubMed ID: 34616410
[TBL] [Abstract][Full Text] [Related]
6. Promiscuous
Scholzen A; Richard G; Moise L; Baeten LA; Reeves PM; Martin WD; Brauns TA; Boyle CM; Raju Paul S; Bucala R; Bowen RA; Garritsen A; De Groot AS; Sluder AE; Poznansky MC
Front Immunol; 2019; 10():207. PubMed ID: 30828331
[No Abstract] [Full Text] [Related]
7. Immunogenicity and Reactogenicity in Q Fever Vaccine Development.
Fratzke AP; van Schaik EJ; Samuel JE
Front Immunol; 2022; 13():886810. PubMed ID: 35693783
[No Abstract] [Full Text] [Related]
8. Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of
Sluder AE; Raju Paul S; Moise L; Dold C; Richard G; Silva-Reyes L; Baeten LA; Scholzen A; Reeves PM; Pollard AJ; Garritsen A; Bowen RA; De Groot AS; Rollier C; Poznansky MC
Front Immunol; 2022; 13():901372. PubMed ID: 35651616
[TBL] [Abstract][Full Text] [Related]
9. Tuning Subunit Vaccines with Novel TLR Triagonist Adjuvants to Generate Protective Immune Responses against
Gilkes AP; Albin TJ; Manna S; Supnet M; Ruiz S; Tom J; Badten AJ; Jain A; Nakajima R; Felgner J; Davies DH; Stetkevich SA; Zlotnik A; Pearlman E; Nalca A; Felgner PL; Esser-Kahn AP; Burkhardt AM
J Immunol; 2020 Feb; 204(3):611-621. PubMed ID: 31871024
[No Abstract] [Full Text] [Related]
10. Comparative efficacy of a Coxiella burnetii chloroform:methanol residue (CMR) vaccine and a licensed cellular vaccine (Q-Vax) in rodents challenged by aerosol.
Waag DM; England MJ; Pitt ML
Vaccine; 1997 Nov; 15(16):1779-83. PubMed ID: 9364683
[TBL] [Abstract][Full Text] [Related]
11. Immunisation with purified Coxiella burnetii phase I lipopolysaccharide confers partial protection in mice independently of co-administered adenovirus vectored vaccines.
Dold C; Zhu H; Silva-Reyes L; Blackwell L; Linder A; Bewley K; Godwin K; Fotheringham S; Charlton S; Kim YC; Pollard AJ; Rollier CS
Vaccine; 2023 May; 41(19):3047-3057. PubMed ID: 37037709
[TBL] [Abstract][Full Text] [Related]
12. Contributions of lipopolysaccharide and the type IVB secretion system to Coxiella burnetii vaccine efficacy and reactogenicity.
Long CM; Beare PA; Cockrell DC; Fintzi J; Tesfamariam M; Shaia CI; Heinzen RA
NPJ Vaccines; 2021 Mar; 6(1):38. PubMed ID: 33741986
[TBL] [Abstract][Full Text] [Related]
13. Antigenic structure of Coxiella burnetii. A comparison of lipopolysaccharide and protein antigens as vaccines against Q fever.
Williams JC; Hoover TA; Waag DM; Banerjee-Bhatnagar N; Bolt CR; Scott GH
Ann N Y Acad Sci; 1990; 590():370-80. PubMed ID: 2378463
[TBL] [Abstract][Full Text] [Related]
14. Vaccines against coxiellosis and Q fever. Development of a chloroform:methanol residue subunit of phase I Coxiella burnetti for the immunization of animals.
Williams JC; Peacock MG; Waag DM; Kent G; England MJ; Nelson G; Stephenson EH
Ann N Y Acad Sci; 1992 Jun; 653():88-111. PubMed ID: 1626897
[TBL] [Abstract][Full Text] [Related]
15. Synthetic Particulate Subunit Vaccines for the Prevention of Q Fever.
Sam G; Plain K; Chen S; Islam A; Westman ME; Marsh I; Stenos J; Graves SR; Rehm BHA
Adv Healthc Mater; 2024 Mar; 13(7):e2302351. PubMed ID: 38198823
[TBL] [Abstract][Full Text] [Related]
16. Guinea pig abscess/hypersensitivity model for study of adverse vaccination reactions induced by use of Q fever vaccines.
Wilhelmsen CL; Waag DM
Comp Med; 2000 Aug; 50(4):374-8. PubMed ID: 11020154
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide epitope mapping across multiple host species reveals significant diversity in antibody responses to
Bach E; Fitzgerald SF; Williams-MacDonald SE; Mitchell M; Golde WT; Longbottom D; Nisbet AJ; Dinkla A; Sullivan E; Pinapati RS; Tan JC; Joosten LAB; Roest HJ; Østerbye T; Koets AP; Buus S; McNeilly TN
Front Immunol; 2023; 14():1257722. PubMed ID: 37954609
[No Abstract] [Full Text] [Related]
18. Standardized guinea pig model for Q fever vaccine reactogenicity.
Baeten LA; Podell BK; Sluder AE; Garritsen A; Bowen RA; Poznansky MC
PLoS One; 2018; 13(10):e0205882. PubMed ID: 30312355
[TBL] [Abstract][Full Text] [Related]
19. The Feasibility of Using
Kumaresan V; Alam S; Zhang Y; Zhang G
Front Immunol; 2021; 12():754690. PubMed ID: 34795669
[TBL] [Abstract][Full Text] [Related]
20. Immunoreactive Coxiella burnetii Nine Mile proteins separated by 2D electrophoresis and identified by tandem mass spectrometry.
Deringer JR; Chen C; Samuel JE; Brown WC
Microbiology (Reading); 2011 Feb; 157(Pt 2):526-542. PubMed ID: 21030434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
